Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVN374)

• Drug Name: Ginkgolide C Drug Info
• Synonyms: Ginkgolide C; BN 52022; SCHEMBL500086; GTPL1863; 15291-76-6; AKOS032961923; LMPR0104540003; C07603

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 24721502
  CAS Number: CAS 15291-76-6
  TTD Drug ID: DMVN374

Molecule-Related Drug Atlas

Drug(s) Targeting Strychnine-binding glycine receptor (GLRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[3]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[4]
GINKOLIDE B	DMLIM7B	Sepsis	1G40-1G41	Terminated	[2]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	DME8VPC	Discovery agent	N.A.	Investigative	[3]
3-demethoxy-3-D-xylopyranosylaminothiocolchicine	DMXFVD1	Discovery agent	N.A.	Investigative	[3]
3-demethoxy-3-L-fucopyranosylaminothiocolchicine	DM4ERYF	Discovery agent	N.A.	Investigative	[3]
3-demethoxy-3D-glucopyranosylaminothiocolchicine	DMID7TC	Discovery agent	N.A.	Investigative	[3]
3-demethoxy-3-D-mannopyranosylaminothiocolchicine	DMALMGH	Discovery agent	N.A.	Investigative	[3]
GINKGOLIDE A	DMKZJ7T	Discovery agent	N.A.	Investigative	[2]
Ginkgolide J	DMUOMP1	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Glycine receptor (GlyR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[3]
ZD-9379	DM3KYO4	Cerebrovascular ischaemia	8B1Z	Phase 1	[5]
UK-240455	DMSCXB7	Nerve injury	ND56.4	Phase 1	[6]
MDL-27531	DMC60S8	Epilepsy	8A60-8A68	Phase 1	[7]
Gavestinel	DM8IL1U	Nerve injury	ND56.4	Discontinued in Phase 2	[8]
GV-196771	DMFN21T	Migraine	8A80	Discontinued in Phase 2	[9]
GW 468816	DMQ92WF	Tobacco dependence	6C4A.2	Discontinued in Phase 2	[10]
M-241247	DMIY51U	Cerebrovascular ischaemia	8B1Z	Terminated	[11]
GINKOLIDE B	DMLIM7B	Sepsis	1G40-1G41	Terminated	[2]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	DME8VPC	Discovery agent	N.A.	Investigative	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycine receptor (GlyR)	TTZ8EM9	GLRA1_HUMAN; GLRA2_HUMAN; GLRA3_HUMAN; GLRA4_HUMAN; GLRB_HUMAN	Inhibitor	[2]
Strychnine-binding glycine receptor (GLRA1)	TTF45NW	GLRA1_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1863).
• [2] Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
• [3] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [4] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [5] Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.
• [6] UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9.
• [7] MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5.
• [8] Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54.
• [9] First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol. 1999 Jun;39(6):560-6.
• [10] A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.J Clin Psychopharmacol.2011 Oct;31(5):597-602.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)